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Abstract— The robustness of a model-based control 
protocol as a less intensive TGC protocol using insulin 
Glargine for provision of basal insulin is simulated in this 
study. To quantify the performance and robustness of the 
protocol to errors, namely physiological variability and 
sensor errors, an in-silico Monte Carlo analysis is 
performed. Actual patient data from Christchurch 
Hospital, New Zealand were used as virtual trial patients.  
Keywords-model-based protocol; less critical patients; 
Monte Carlo; tight glycaemic control;  
I. INTRODUCTION  
 There is a pressing need for insulin delivery 
protocols that can be successfully implemented with 
minimal clinical effort, burden and resources. Based on 
current evidence from critically ill and surgical patients, 
it is logical to expect that maintenance of 
normoglycaemia within less critical patients such in 
high dependency units (HDU) would limit potential 
complications associated with elevated blood glucose 
levels. This assumption is not unreasonable as patients 
in the ICU and within HDU share an accelerated 
catabolic, hyperglycaemic state that also reduces the 
immune response. The challenge is to find and 
implement glycaemic goals with a standardized, safe 
and effective protocol.  
 
 The SPRINT-1U+Glargine protocol was 
developed to simulate a less intensive TGC protocol to 
support the transition of patients from ICU to less acute 
wards. Glargine is injected 1-2x/day, so it can 
potentially reduce the workload to match clinical 
resources. The protocol uses an integrated pharmaco-
kinetics/dynamic model of insulin Glargine intravenous 
insulin and glucose from [1] and [2]. To quantify the 
performance and robustness of the protocol to errors, 
namely physiological variability and sensor errors, an 
in-silico Monte Carlo analysis is performed. The main 
assessments taken into account are accuracy and 
repeatability. 
II. SYSTEM MODEL 
A four compartment description of subcutaneous 
insulin kinetics is presented, where Glargine is modelled 
to appear in its precipitate, hexameric, dimeric / 
monomeric, and (local) interstitium states. The 
underlying structure of this pharmacokinetics model is 
adopted from [1]. The model describes the 
pharmacokinetics processes following subcutaneous 
administration of Glargine: 
 
Insulin Glargine Compartmental Model. 
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Dimeric/ Monomeric State:         
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where all variables in Equations (1)-(4) are defined in 
Table 1 
Table 1: Description of Glargine Model Parameters. 
Parameter Description 
xh,gla (t)  Mass in glargine hexameric compt. [mU] 
pgla (t)  Mass in glargine precipitate compt. [mU] 
xdm(t) Mass in dimer/monomer compartment [mU] 
xi(t) Mass in the interstitium compartment [mU] 
rdis,max Max glargine precip. dissolution rate [mU/min] 
utotal,gla(t) Insulin glargine input [mU/min] 
up,gla(t)  Glargine precipitate state insulin input [mU/min] 
uh,gla(t) Glargine hexamer state insulin input [mU/min] 
n Decay rate of insulin from plasma [1/min] 
αI Saturation of plasma insulin disappearance 
[L/mU] 
uex Exogenous insulin input [mU/min] 
kprep,gla Glargine precipitate dissolution rate [min-1] 
k1 Hexamer dissociation rate [min-1] 
k1,gla Glargine hexamer dissociation rate [min-1] 
k2 Dimeric/monomeric insulin transport rate into 
interstitium [min-1]    
k3 Interstitium transport rate into plasma [min-1] 
kd I  Rate of loss from interstitium [min-1] 
kd Rate of diffusive loss from hexameric and 
dimeric 
um,gla(t) Glargine dimer/monomer state insulin input 
mb Body Mass [kg] 
 
Insulin-Glucose Model: 
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where all variables in Equations (5)-(10) are defined in 
Table 2: 
Table 2: Description of Insulin-Glucose Model Parameters. 
G Total plasma glucose [mmol/L] 
I Plasma insulin [mmol/L] 
Q Interstitial insulin [mU/L] 
EGP Endogenous glucose production [mmol/min] 
pG Glucose clearance [1/min] 
SI Insulin sensitivity [L/(mU.min)], 
uex Exogenous insulin input [mU/min] 
D Enteral dextrose infusion 
P1 Represents stomach [mmol/min] 
P2 Represents gut [mmol/min] 
P Glucose appearance [mmol/min] 
n Decay rate of insulin from plasma [1/min] 
k Effective life of insulin in the system 
d1 Transport rate [1/min] 
d2 Transport rate [1/min] 
αG Saturation of insulin-dependent glucose clearance 
[L/mU] 
αI Saturation of plasma insulin disappearance [L/mU] 
VG Glucose distribution volume [L] 
VI insulin distribution volume [L] 
III. METHOD 
 Table 3 shows the details for 30 patients 
chosen from the SPRINT cohort [3]. Males are 70% of 
patients. Median age of these patients is 53.5 [IQR: 
44,73] years old. Median APACHE II score is 18 with 
IQR=[12,19]. The average length of stay is 6.6 days 
(Range: 5.6-10 days). Mortality is 0 for the selected 
patients. The effectiveness of Glargine for blood 
glucose control is assessed in silico.  
 Glargine is intended for patients recovering 
from critical illness, for whom metabolic homeostasis 
had been regained. Patients selected for simulation are 
those who exhibit metabolic stability within 30 hours of 
ICU admission. Metabolic stability is defined: 
 
• Hourly insulin boluses ≤ 3U for at least 12 
hours. 
• Hourly feed rate of ≥60% of individual 
patient's goal feed rate. 
Time-varying insulin sensitivity, SI was fitted hourly to 
clinical patient data using Equations (5)-(11) and an 
integral fitting method [4]. Constraints are placed on SI 
to ensure a physiologically valid range. The resulting 
time-varying SI profiles represent time-varying 
metabolic status for individual patients. Thus, these 
profiles of SI can act as clinically validated virtual 
patients for testing different glycaemic control protocols 
[5].  
 
Table 3: Long-term virtual trial patient cohort (N=30, 4,420 total 
hours equivalent to 184.2 day) 
Patient 
ID 
Length 
of Stay 
(hr) 
Medical Group 
 
APACHE 
11 Score Age Sex 
5006 161 Respiratory 23 44 F 
5013 90 Respiratory 18 56 F 
5033 100 Trauma 29 66 F 
5054 158 Respiratory 18 75 M 
5060 271 Gastrointestinal 15 79 M 
5061 140 Trauma 16 22 M 
5071 107 Trauma 12 49 M 
5076 240 Gastrointestinal 12 32 M 
5086 127 Respiratory 32 64 M 
5101 280 Neurological 19 50 M 
5104 113 Trauma 18 18 M 
5122 159 Trauma 19 73 M 
5124 147 Respiratory 16 74 M 
5149 325 Surgical 21 60 M 
5158 103 Neurological 22 68 F 
5173 295 Respiratory 19 67 F 
5188 129 Trauma 14 73 F 
5207 155 Respiratory 19 42 F 
5233 39 Gastrointestinal 16 76 M 
5276 87 Septic Shock 18 18 M 
5279 85 Trauma 18 45 M 
5280 141 Trauma 18 45 M 
5288 77 Meningococcus 23 21 F 
5299 103 Respiratory 20 56 F 
5310 34 Neurological 19 60 F 
5315 196 Respiratory 18 19 M 
5317 136 Toxicology 19 23 M 
5322 136 Respiratory 15 72 F 
5351 166 Respiratory 12 76 M 
5376 120 Surgical 16 56 F 
  
 Virtual trials are performed using SPRINT 
with daily (24 hours) doses of Glargine, where the first 
dose is given 12 hours after ICU admission. The initial 
Glargine bolus is the sum of SPRINT insulin boluses 
administered during the previous 12 hours. The 
following Glargine boluses are calculated as being half 
of the total daily insulin (IV boluses + Glargine) from 
the previous day. Each bolus is capped at 40U for safety 
against hypoglycaemia. 
 The SPRINT-1U+Glargine protocol seeks to 
use Glargine, gradually replacing intravenous insulin. 
As noted, it is a first step and protocol towards 
developing a complete, more final solution.  
A. Monte Carlo Error 
 For each patient, 100 simulations were 
performed to generate statistics on performance. Each 
virtual trial had added sensor noise simulated to be 
normally distributed with a standard deviation of 5%, 
and max error of ±4 standard deviations, with a 
saturated max of ±20%. The latest generation of glucose 
meters is more advanced with greater accuracy [6]. In 
addition, subcutaneous Glargine absorption variability 
was added. Hence, the error simulated is typical of 
today’s devices or slightly larger. 
 The parameters , kprep,gla, k1gla, and αgla are 
Glargine pharmacokinetics parameters varied to 
generate a range of valid possible values of maximal 
plasma insulin concentration, Cmax and time to 
maximal plasma insulin, Tmax, as reported in literature. 
Using a lognormal distribution in the Glargine model 
parameters eliminates non-physiological negative 
values, as shown in Fig. 2. 
 
 (a) αgla 
 
(b) kprep,gla 
 
(c) k1,gla 
 
Figure 2: Histogram plot of the actual variability of Glargine 
pharmacokinetics parameters, kprep,gla, k1gla, and αgla, and the 
frequency they occurred in the 100 Monte Carlo simulations for 
Patient 5376.  
 
Thus, variability is accounted for in Glargine PK 
parameters and glucose sensor error. There are 3000 
simulations in total (30 patients X 100 simulations), 
each being unique due to different random errors 
generated. Simulated error reflects the clinical 
variability, which gives a realistic feature to assess the 
model based control protocol. The main assessments 
taken into account are accuracy and repeatability. 
Safety and performance are the two primary criteria of 
the controller, evaluated by avoidance of 
hypoglycaemia (<2.2mmol/L), median and IQR of 
blood glucose measurements, percentage in desired 
band (4.0-6.1mmol/L, 4.0-7.0mmol/L), amount of 
insulin prescribed (IV boluses+Glargine), amount of 
nutrition given, and nursing effort intensity based on the 
number of interventions required. 
IV.  RESULTS 
 Table 3 shows the results of Monte Carlo 
simulations for the 30 patients’ cohort. The result of 
each MC performance measurement is almost similar to 
the non error simulations. The primary overall result is 
that the variations and errors considered do not appear 
to have any great impact on the protocol design or its 
ability to manage patient’s variability. It is important to 
note that median (IQR) results in Table 3 show the 
middle, much more likely the, 50% of the results. 
Hence, this result should hold as a general trend across 
a wide range of possibilities. This Monte Carlo virtual 
analysis result is parallel with Monte Carlo analysis of 
SPRINT and other protocols using clinically validated 
virtual patients, which revealed little difference with 
added measurement error. Overall, it can be concluded 
that the robustness of the SPRINT-1U+Glargine 
protocol in a noisy clinical environment is validated 
with this Monte Carlo analysis. 
 
Table 3: Per-patient performance measurement with and without 
Monte Carlo 
Performance MC Error Without MC Error 
BG   
mmol/L 
5.65 
[IQR:5.27-6.16] 
5.62 
[IQR:5.12,6.28] 
% Time band   
4-6.1     
65 
[IQR:55.12,72.72] 
66.12 
[IQR:57.14,74.21] 
% Time Band 
4-7.0 
87.19 
[IQR:81.39,89.84] 
86.46 
[IQR:83.88,90.65] 
Nursing Effort 36 
[IQR:34,38] 
36 
[IQR:34,38] 
Total Insulin 
U/day 
70.8 
[IQR:61.67,74.47] 
71.2 
[IQR:62.5,75.07] 
Glargine Daily 
U\day 
35.84 
[IQR:32.03,36.81] 
35.91 
[IQR:32.11,36.84] 
IV Daily 
U/day 
37.23 
[IQR:28.41,40.11] 
35.20 
[IQR:29.11,40.97] 
Feed 
Gram/day 
109.87 
[88.29,145.19] 
109 
[IQR:78.45,125] 
Hypo 0 0 
Figure 3 is the BG profile comparison for a sample 
patient with median of 100 MC simulations against the 
simulations without introduced error. This sample 
This work is sponsored in part by UNITEN. 
patient is representative of the cohort. Both resulting 
BG profiles are almost similar as expected, since the 
median would be expected to be as similar as possible 
to the actual profile overall possible random variations 
and errors. The largest differences would be seen at the 
5th and 95th percentile. Hence, an upper and lower 
envelope representing the 5th and 95th percentile of all 
possible blood glucose concentration is shown in Figure 
3(b). The 5th and 95th percentile range are quite tight 
particularly towards the end of Patient 5376's stay from 
6000 to 7500 mins. The results also show that BG 
values are more varied between the values of 3-6 
mmol/L, where the biggest difference between the 95th 
percentile range and median MC simulations could be 
seen around 1500-5500 mins.  
V.  DISCUSSION 
 Monte Carlo simulations allow sensor errors to 
be generated in the data, as well as adding valid 
physiological variances. Both are instrumental in 
portraying the real and potentially quite different 
physiological conditions of patients, which mix with 
sensor errors to yield the glycaemic variability observed 
clinically. In particular, in any clinical environment, a 
validated in silico virtual patient environment offers the 
ability to include the effect of parameter uncertainty and 
sensor error in the virtual simulations. The specific 
Monte Carlo results presented confirm the robustness of 
SPRINT-1U+Glargine protocol to realistic, 
physiological variations and sensor errors. The results 
clearly define, quantitatively the impact of variability 
across the cohort and for individual patients. Finally, 
the results provide a qualitative measure robustness and 
confidence in the developed protocol. 
   
 
(a) Median MC Error 
 
(b) Without MC Error 
 
Figure 3. Comparison of BG profile for Patient 5376 simulated 100 
runs with and without error. Figure 7.3(a) compares the actual BG 
profile in solid blue line, (-) against median of 100 MC error runs 
shown as blue dotted line, (···). Figure 7.3(b) compares the actual BG 
profile depicted in solid blue line  (-) against the 5th and 95th 
percentile of 100 MC error. The 5th percentile error is shown in red 
dotted line, (···) while 95th percentile error is in red dashed line (- -). 
  
VI. CONCLUSION 
 An effective, robust and safe subcutaneous 
transition protocol is presented. In-silico analysis 
accurately quantified nursing effort and performance. 
Monte Carlo analysis was used to test the robustness of 
the control protocol and robustness is achieved with the 
ability of the control protocol accounting for possible 
BG concentrations and variations of Glargine 
absorption. In particular, the middle 50% of likely 
outcomes indicates that there is no change of clinical 
significance in control quality and nursing effort. The 5-
95% range shows that safety and acceptable control 
quality are guaranteed. Overall, the results meet the 
primary goal of the analysis to justify a clinical pilot 
study to validate these in-silico results. 
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